Results 71 to 80 of about 24,362 (263)
Epileptic Disorders, EarlyView.Abstract Background and Objectives Muscle‐Eye‐Brain disease (MEB) is a dystroglycanopathy that belongs to the congenital muscular dystrophies. Central nervous system manifestations include congenital brain abnormalities, neurodevelopmental delay, and epilepsy, making it a rare but important cause of developmental and epileptic encephalopathy.
Stefania Kalampokini +6 more
wiley +1 more source
Case Reports in Medicine, 2012 Two cases of patients experienced subsyndromal depression after manic or mixed hypomanic and depressive episodes due to bipolar I (case 1) and II (case 2) disorders prior to the use of lamotrigine.
Katsumasa Muneoka +6 more
doaj +1 more source
Clinical Case Reports, 2018 Key Clinical Message Lamotrigine is a sodium and calcium channel blocker, used to treat seizures in people. Dogs metabolize Lamotrigine to a cardiotoxic metabolite that causes severe, often fatal ventricular arrhythmias.
Tara J. Bellis, Laura Gibeon
doaj +1 more source
A guide to neuromodulation in drug‐resistant epilepsy
Epileptic Disorders, EarlyView.Abstract Neuromodulation is approved for the treatment of drug‐resistant epilepsy. It has been increasingly utilized over the past two decades with the approval of deep brain stimulation (DBS) and responsive neurostimulation (RNS) in addition to vagus nerve stimulation (VNS)—particularly in patients who are not deemed to be good resective surgical ...
Prachi Parikh +10 more
wiley +1 more source
Lamotrigine toxicity secondary to sertraline
, 1998 Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants. We investigated initial drug-drug interactions between lamotrigine and sertraline.
Kaufman, Kenneth R., Gerner, Robert
core +1 more source
Monitoring salivary lamotrigine concentrations
, 2006 Lamotrigine concentrations were measured simultaneously (as far as was feasible) in stimulated and unstimulated saliva samples, and in plasma, from seven adult volunteers over a 32 h period following a single 50 mg dose of the drug, and in 20 children ...
Dickinson, Ronald G. +4 more
core +1 more source
The second unprovoked seizure in a cohort of treated patients with a first unprovoked seizure
Epileptic Disorders, EarlyView.Abstract Objectives To evaluate the rate of a second unprovoked seizure in antiseizure medications (ASMs)‐treated patients following a first unprovoked seizure and to identify potential risk factors associated with its occurrence. Methods A retrospective review of the computerized database and the medical records of all the patients who presented to ...
Revital Gandelman‐Marton +1 more
wiley +1 more source
The outcomes of consecutive pregnancies in Australian women with epilepsy
Epileptic Disorders, EarlyView.Abstract Objective To investigate the extent to which seizure control and the occurrence of fetal malformation in an initial pregnancy can serve to anticipate the outcome in the next pregnancy. Methods We analyzed the records of the Raoul Wallenberg Australian Register of Antiepileptic Drugs in Pregnancy for seizure control and fetal malformation data ...
Frank Vajda +7 more
wiley +1 more source
, 1996 Cutaneous rash is one of the commonest adverse events associated with lamotrigine. We assessed whether the risk is increased in patients receiving concomitant valproate therapy in a population of 103 adult patients with intractable epilepsy, who had ...
Russo, M +4 more
core
Population pharmacokinetics of lamotrigine
, 2001 The present study estimated the population pharmacokinetics of lamotrigine in patients receiving oral lamotrigine therapy with drug concentration monitoring, and determined intersubject and intrasubject variability.
Chan, V. +6 more
core +1 more source